Explore our comprehensive portfolio that addresses the complete care continuum for many of the world’s most threatening diseases. 

Discover the stories of pioneers pushing the boundaries of what’s possible in healthcare to help improve people’s lives around the world.

Patient-centered innovation has been and always will be at the core of our company. Dive deeper into our fascinating technologies.

We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. Learn more about our purpose, our innovation leadership, our culture, and our strategy.

  1. Home

  2. Press center
  3. Press releases
  4. Siemens Healthineers sustains strong revenue momentum in the third quarter
Press release

Siemens Healthineers sustains strong revenue momentum in the third quarter

Siemens Healthineers AG today announces its results for the third quarter, ending June 30, of fiscal year 2023.
Published on August 2, 2023

Q3 Fiscal Year 2023 

  • Equipment orders clearly exceeded strong equipment revenues on a broad basis; equipment book-to-bill ratio 1.11 
  • Comparable revenue growth very strong at 10.1% excluding rapid COVID-19 antigen tests; taking into account the tailing-off rapid antigen test business, revenue rose by 3.6% on a comparable basis 
  • Imaging showed comparable revenue growth of 15.2%; adjusted EBIT margin of 21.8% clearly above the prior-year quarter 
  • Diagnostics revenue fell by 20.1% on a comparable basis due to tailing-off rapid COVID-19 antigen test business; excluding antigen tests comparable revenue grew 2.0%; adjusted EBIT margin -0.5%; excluding rapid antigen tests and transformation costs 1.0% 
  • Varian showed comparable revenue growth of 6.7%; adjusted EBIT margin 12.1% 
  • Advanced Therapies posted comparable revenue growth of 11.9%; adjusted EBIT margin clearly higher than in the prior-year quarter at 15.3% 
  • Overall adjusted EBIT margin fell slightly to 14.2%, mainly due to drop out of contributions from rapid COVID-19 antigen tests 
  • Adjusted basic earnings per share rose to €0.53

Outlook for Fiscal Year 2023 

We confirm our expectation for comparable revenue growth of -1% to 1% (6% to 8% excluding revenue from rapid COVID-19 antigen tests) and adjusted basic earnings per share of €2.00 to €2.20. 

Bernd Montag, CEO of Siemens Healthineers AG: 

»The Siemens Healthineers team once again delivered a quarter of strong growth. This clearly underlines the special relevance and meaning of our innovations for our customers and their patients worldwide.«

Download Quarterly Statement(pdf, 279.18 KB)

Siemens Healthineers 2023

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies are continuously developing their product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care. In fiscal 2022, which ended on September 30, 2022, Siemens Healthineers, which has approximately 69,500 employees worldwide, generated revenue of around €21.7 billion and adjusted EBIT of almost €3.7 billion. Further information is available at www.siemens-healthineers.com.